Foundations Investment Advisors LLC Has $864,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Foundations Investment Advisors LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 142.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,807 shares of the medical instruments supplier’s stock after purchasing an additional 2,235 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $864,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BDX. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the third quarter valued at about $33,000. Tompkins Financial Corp grew its position in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Roland Goette sold 638 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $246.85 on Thursday. The company has a market capitalization of $71.59 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 1.72 and a beta of 0.39. The company has a 50-day moving average of $229.10 and a 200-day moving average of $233.46. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $250.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the business earned $3.42 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.69%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.